Agree that rgs announcement is positive news for the sector. I was skeptical they would deliver on time but they have. And more positive developments are good for the regenerative space.
rgs has a positive Japan partnership & now phase I results. Both promoted as re-rate catalysts but rgs SP declined after the first and remains flat now.
Meanwhile msb value has moved a lot over the past year. I moved my regenerative medicine holdings from rgs to msb last year and that has turned out very positive.But I am surprised rgs SP stays flat as a tack.
msb has keen interest while rgs barely rates despite positive news. Is that msb's much larger mkt cap? Better mgmt and communications? msb further along with trials & closer to commercial viability? Or are rgs still wearing the ABC media drama?
But hopefully a rising tide of good regenerative medicine news lifts all boats.
Agree that rgs announcement is positive news for the sector. I...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |